by 340B Report
Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report’s newsroom for a candid, insider’s perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
Language
🇺🇲
Publishing Since
9/3/2024
Email Addresses
1 available
Phone Numbers
0 available
April 14, 2025
<p dir="ltr">In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the latest states to enact contract pharmacy access laws, updates in key lawsuits and new U.S. Department of Health and Human Services (HHS) restructuring efforts.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>New State Contract Pharmacy Access Laws</strong><br /> Will highlights new contract pharmacy access laws enacted in Nebraska and Utah, including when they take effect and how their respective state governors approached the legislation. He also briefly discusses New Mexico’s newly enacted contract pharmacy access law, which does not take effect until 2026 and is the only enacted state contract pharmacy protection statute that only applies to health centers.</p> <p dir="ltr"><strong>Key Updates in Drug Industry Lawsuits and State Enforcement Action</strong><br /> Will also breaks down a Minnesota federal district judge’s order to dismiss two drug industry lawsuits challenging that state’s contract pharmacy access law. The judge ruled that the drugmakers had no legal standing to sue the state over its contract pharmacy law since Minnesota’s law—unlike most other existing state contract pharmacy protection statutes—has no enforcement mechanism. Meanwhile, in Arkansas, a state official recently ordered AstraZeneca to restore access to 340B drugs at all contract pharmacy locations. AstraZeneca had been the only major manufacturer not to comply with Arkansas’ first-in-the-nation contract pharmacy access law after a federal appeals court panel unanimously upheld the statute in March 2024.</p> <p dir="ltr"><strong>A New CMS Leader and HHS Restructuring</strong></p> <p dir="ltr">Shannon and Bella provide an update on 340B-related activity at the federal level. Bella discusses the U.S. Senate’s recent confirmation of Mehmet Oz as the new administrator of the Centers for Medicare and Medicaid Services (CMS). Shannon highlights the recent restructuring at HHS and rumored efforts to move the 340B program into CMS. </p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. <a href= "https://verity-solutions.com/">Verity Solutions</a> sponsored this week’s episode. Verity’s innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">We’re offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.</p>
March 31, 2025
<p dir="ltr">In this episode, the Inside 340B Report team dives into a flurry of activity at the state and federal levels. Publisher and CEO Ted Slafsky and Associate Editor/Senior Writers Shannon Young and Will Newton break down the unprecedented wave of state-level 340B contract pharmacy access and provider reporting bills, explore key federal movements, including the latest on the bipartisan U.S. Senate working group behind the SUSTAIN 340B Act, and provide an update on 340B rebate litigation.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>State Legislative Activity Heats Up</strong><br /> The team discusses the recent surge in legislative action on state 340B bills as more than 25 states have introduced contract pharmacy access bills in 2025. South Dakota and Utah recently enacted contract pharmacy laws in 2025, joining eight other states that passed similar bills in previous years, while bills in New Mexico and North Dakota are awaiting action from their state governors. Will also highlights several state bills that would place a range of reporting requirements—and in some cases significant restrictions—on 340B providers.</p> <p dir="ltr"><strong>Federal Legislative Developments and Bipartisan Efforts</strong><br /> Shannon provides updates on the latest developments on the 340B front in Washington, D.C., including the new members of the bipartisan group of six senators working on 340B overhaul legislation known as the SUSTAIN 340B Act. She and Ted also highlight other federal bills that could resurface this session, including the provider-supported 340B PATIENTS Act and drug industry-backed 340B ACCESS Act. The team also provides an update on Mehmet Oz’s nomination to lead the Centers for Medicare & Medicaid Services (CMS), focusing on a new Washington Post story that highlighted 340B Report’s previous reporting on his undisclosed ties to ZorroRx, a health benefits company that partners with 340B hospitals. Despite facing new ethics concerns, Oz has not drawn much scrutiny from lawmakers during the confirmation process over his 340B ties or stance on the program—a shift from previous nominees.</p> <p dir="ltr"><strong>Rebate Litigation Developments</strong><br /> Will explains recent developments in ongoing lawsuits that pharmaceutical giants, like Johnson & Johnson and Eli Lilly, have filed against the federal Health Resources and Services Administration (HRSA) in their attempts to unilaterally impose 340B rebate models. Notably, in a series of recent court filings, President Donald Trump’s (R) administration has chosen to continue to defend HRSA’s long-standing position that drugmakers cannot implement 340B rebate models without explicit agency approval, offering some relief to the 340B provider community.</p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by <a href= "http://compassrx.com">CompassRx</a>, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize your 340B savings and operational efficiency.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href= "https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.<strong id= "docs-internal-guid-ff982063-7fff-c33d-0f37-44143b25da57"></strong></p>
March 14, 2025
<p dir="ltr">In this episode of Inside 340B Report, Ted Slafsky, Will Newton and Bella Czajkowski explore the latest developments in the 340B world at both the state and federal levels. They cover the progress of contract pharmacy access bills across the country—including a breaking news development—plus dark money efforts to oppose the legislation. They also break down key updates in drugmaker rebate lawsuits and provide an update on federal budget talks including major cuts expected for the Medicaid program and where we may be headed on the 340B program.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>Contract Pharmacy Bills Progress, Despite Resistance </strong> Will summarizes recent key votes on state contract pharmacy access bills and provider reporting legislation. He also breaks the news that South Dakota became the first state in 2025 to enact contract pharmacy protections after hearing from the governor’s office mid-recording. Meanwhile, Bella highlights the tactics of dark money efforts to oppose contract pharmacy legislation through misleading ads, noting that many of the efforts appear to be backfiring.</p> <p dir="ltr"><strong>Drugmaker Rebate Litigation Heats Up </strong> The team discusses five drugmakers’ ongoing legal efforts to implement 340B rebate models without approval from the Health Resources and Services Administration. Bella and Will explain the significance of the recent decision allowing the hospital advocacy group 340B Health and two of its member hospitals to intervene in four of those cases, all while other major provider advocacy groups have filed amicus briefs opposing the rebate models.</p> <p dir="ltr"><strong>Budget Talks and the Looming Federal Shutdown </strong> With crucial budget negotiations unfolding in Congress, Ted breaks down the potential impact of proposed healthcare funding cuts totaling $880 billion over the next decade. These cuts could have significant effects on Medicaid, directly affecting 340B providers and the patients they serve. Ted notes that 340B stakeholders should keep a close eye on Capitol Hill as budget battles continue, especially given the possibility of a government shutdown. He also talks about the leaders of key committees with jurisdiction over the 340B program and what that could mean for 340B stakeholders.</p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. <a href= "https://www.thepharmaforce.com/">PharmaForce</a> is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We're grateful to PharmaForce for making this episode possible.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href= "https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.</p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
